21 February 2017
News and Views
Links and Services
This week's issue of the New England Journal of Medicine examines the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer.
In a phase 1–2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial c
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors